why is tirzepatide no longer available Update: On December 19th the FDA ruled the tirzepatide shortage was resolved, however giving a grace period for compounding pharmacies to continuing manufacturing. This grace period is 60 days. On A Major GLP-1 Drug Shortage

There is no official guidance from the FDA on the frequency or total number of lipotropic injections for weight loss

You travel constantly or hate daily injections CJC-1295 with DAC is the only one of the three that dosable weekly

While GLP-1 remains in the testing stage, attending NA meetings can be a head start toward recovery

Incretin agonism reduces appetite, promotes insulin release, and slows gastric transit, which together lead to profound weight loss with improvements in metabolism 16

Clinical trials show tirzepatide produces 2022% average weight loss versus 1517% for semaglutide, but individual outcomes vary